Powered by

NeuroRx Initiates Phase 2/3 Study of Inhaled ZYESAMI™ for Severe COVID-19 with UCI Health

Feb 03, 2021 - PR Newswire

PR Newswire

NeuroRx, Inc. today announced initiation of a Phase 2/3 clinical trial investigating the role of inhaled ZYESAMI™ (aviptadil) for the treatment of patients with Severe COVID-19 in partnership with UCI Health of the University of California, Irvine. UCI Health was also a key site in the recently-completed study of ZYESAMI™1 for intravenous administration in patients with Critical COVID-19 Respiratory Failure.  The objective of the current study is to determine whether avipt...